Peer reviewed publications
124 Nagra M, Tsam F, Ward S, Ur E. Animal vs Plant-Based Meat: A Hearty Debate. Can J Cardiol. 2024 Jul;40(7):1198-1209. doi: 10.1016/j.cjca.2023.11.005. Epub 2024 Jun 26. PMID: 38934982
123 Felicia Tsam, Ur E. Plant Based Diets for the Prevention and Treatment of Diabetes: A Mini-Review. Curre Res Diabetes & Obes J 2021; 14(2)
122 Samson S, Nachtigall L, Fleseriu M, Baldys WA, Jensterle M, Ur E, Molitch ME, Ludlam W, Patou G, Haviv A, Biermasz N. Sustained response to treatment with oral octreotide capsules: Results from the phase 3, randomized, double blind, placebo-controlled optimal study. InEndocrine Abstracts 2020 Aug 21 (Vol. 70). Bioscientifica
121 Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. The Journal of Clinical Endocrinology & Metabolism. 2020 Oct;105(10):e3785-97.
120 Atkins P, Ur E. Primary and ipilimumab-induced hypophysitis: a single-center case series. Endocrine Research. 2020 Oct 1;45(4):246-53.
119 Samson SL, Nachtigall LB, Fleseriu M, Ur E, Ludlam WH, Patou G, Haviv A, Gilgun-Sherki Y, Biermasz N, Strasburger CJ, Kennedy L. MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study. Journal of the Endocrine Society. 2020 Apr;4(Supplement_1):MON-323.
118 Zamora JM, Joy G, Mattman A, Ur E. Treating hyperthyroidism in the critically ill patient with rectal methimazole. Clinical Endocrinology. 2020 Feb 5;92(5):485-7.
117 Ur E. Re: Diabetes in BC Reply. BRITISH COLUMBIA MEDICAL JOURNAL. 2019 Jan 1;61(1):11-2.
116 Clement M, Paty B, Mancini GB, Miller D, Mudaliar A, Shu D, Thompson D, White A, Ur E. Challenges to managing type 2 diabetes in British Columbia: Discordant guidelines and limited treatment options. British Columbia Medical Journal. 2018 Nov 1;60(9).
115 Ur E. Diabetes in British Columbia: Starvation in the midst of plenty. BRITISH COLUMBIA MEDICAL JOURNAL. 2018 Nov 1;60(9):436-8.
114 Li D, Elliott T, Klein G, Ur E, Tang TS. Diabetes Nurse Case Management in a Canadian Tertiary Care Setting: Results of a Randominzed Controlled Trial. Can J Diabetes 2017 Jun;41(3):297-304
113 Serlin Y, Shafat T, Levy J, Winter A, Shneck M, Knyazer B, Parmet Y, Shalev H, Ur E, Friedman A.(2016). Angiographic evidence of proliferative retinopathy predicts neuropsychiatric morbidity in diabetic patients. Psychoneuroendocrinology.67: 163-70.
112 Dawes D, Ashe M, Campbell K, Cave D, Elley CR, Kaczorowski J, Sohal P, Ur E, Dawes M.(2015).Preventing diabetes in primary care: a feasibility cluster randomized trial. Can J Diabetes. 2015 39(2): 111-116
111 Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E.(2014). Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel.Can J Cardiol. 2014 Apr;30(4):377-80. 30(4): 377-80.
110 Rabkin SW , Langer A , Ur E , Calciu CD , Leiter LA. (2013). Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy. Hypertension research : official journal of the Japanese Society of Hypertension. ,
109 HarrisD,BartsA,ConnorsJ,DahlM,ElliottT, KongJ, KeaneT,ThompsonD, StaffordS, UrE , Sirrs S. (2013). Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing
cancer therapy: an observational cohort study.Current oncology (Toronto, Ont.). 20(6),
108 Anderson TJ , Grégoire J , Hegele RA , Couture P , Mancini GB , McPherson R , Francis GA , Poirier P , Lau DC , Grover S , Genest J , Carpentier AC , Dufour R , Gupta M , Ward R , Leiter LA , Lonn E , Ng DS , Pearson GJ , Yates GM , Stone JA , Ur E. (2013). 2012 update of the canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. The Canadian journal of cardiology. 29(2),
107 Braga MF, CasanovaA, Teoh H, GersteinHC, Fitchett DH, HonosG,McFarlanePA,UrE, Yale JF , Langer A , Goodman SG , Leiter LA ,. (2012). Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. International journal of clinical practice. 66(5),
106 ValletteS,EzzatS,ChikC,UrE,ImranSA,UumS,RiveraJ,Caspar-BellG,SerriO.(2012). Emerging Trends in the Diagnosis and Treatment of Acromegaly in Canada. Clinical endocrinology.
105 Almalki MH , Ur E , Johnson M , Clarke DB , Imran SA. (2012). Management of prolactinomas during pregnancy -- a survey of four Canadian provinces.Clinical and investigative medicine. Médecine clinique et experimentale. 35(2),
104 Almalki MH , Chesover AD , Johnson MD , Wilkins GE , Maguire JA , Ur E. (2012). Characterization of management and outcomes of patients with acromegaly in Vancouver over 30 years.Clinical and investigative medicine. Médecine clinique et experimentale. 35(1)
103 Klarenbach S , Cameron C , Singh S , Ur E. (2011). Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 183(16)
102 ACCORD Study Group (Ur E) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 362(17):1575-85.
101 ACCORD Study Group (Ur E), Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. (2010) 362(17):1563-74.
100 ACCORD Study Group; ACCORD Eye Study Group (Ur E). Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. (2010) 363(3):233-44.
99 Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L,, Krikorian A, O'Connor P, Pop- Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I (Ur E); ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. (2010) 376(9739):419-30.
98 Teoh H, Braga MF, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan MK, Ur E, Yan AT, Zinman B, Leiter LA; on behalf of the T2DM QUERI Investigators. Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). Diabetes Care. (2010) 33(12):2558-2560.
97 Cameron C, Coyle D, Ur E, Klarenbach S. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ. (2010) 182(1):28-34.
96 Braga M, Casanova A, Dawson KG, Gerstein HC, Fitchett DH, Harris, SB, Honos G, McFarlane PA, Steele, A, Ur E at al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiology (2010) 26(6):297-302.
95 Imran SA, Ransom TPP, Buth KJ, Clayton D, Al-Shehri B, Ur E et al. Impact of admission serum glucose level on in-hospital outcomes following coronary artery bypass grafting surgery. Can J Cardiology (2010) 151-42009)
94 Ur E, Langer A, Leiter L, Rabkin S, Calciu C. On behalf of the CANACTFAST Study Investigators. Achieving cholesterol targets by individualizing starting doses of statin according to baseline LDL-C and CHD Risk Category: The CANACTFAST Study. Can J Cardiology (2010) 26(2):80-6
93 Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A,Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. (2009) 25(10):567- 79.
92 Ezzat S, Gaspo R, Serri O, Ur E, Chik CL. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Clin Invest Med. (2009) 1;32(6):E265.
91 Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA (Ur E); Look AHEAD and ACCORD Research Groups. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clin Trials. (2009) 6(5):416-29.
90 Imran SA, Fleetwood IG, O'Connell CM, Ransom TP, Mulroy LA, Ur E, Clarke DB. Outcome of stereotactic radiotherapy for patients with uncontrolled acromegaly. Can J Neurol Sci. (2009)J 6(4):468-74.
89 Woo V (Ur E); CDA 2008 Clinical Practice Guidelines Steering Committee. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes response to Nathan et al. Diabetes Care. 2009 Mar;32(3):e34
88 Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon (Ur E)J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. (2008) 30(12):2298-313
87 ADVANCE Collaborative Group (Ur E). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 358(24):2560-72 (2008)
86 Action to Control Cardiovascular Risk in Diabetes Study Group (Ur E). Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med 2008;358(24):2545-59
85 Chaturvedi N and DIRECT Programme Study Group (Ur E). Effect of Candesartan in prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet 2008;372(9647):1394-402
84 Sjolie AK and DIRECT Programme Study Group (Ur E). Effect of Candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2):a randomized placebo-controlled trial Lancet 18; 372(9647):1385-93 (2008)
83 Imran SA, Ur E. Atypical ketosis-prone diabetes Can Fam Phys. 54(11):1553-4 (2008)
82 Ur E, Chiasson J, Ransom T, Rowe R. Definition, Classification and Diagnosis of Diabetes and Other Dysglycemic Categories. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada (2008)
81 Ur E, Chiasson J, Ransom T, Rowe R. Prevention of Diabetes. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada (2008)
80 Ur E, Chiasson J, Ransom T, Rowe R. Screening for Type 1 and Type 2 Diabetes. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada (2008)
79 Ur E, Chiasson J, Ransom T, Rowe R. Prevention of Diabetes. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada (2008)
78 Kahn SE, ADOPT Study Group (Ur E). Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31(5):845-51 (2008)
77 MacKinnon NJ, Hartnell NR, Black EK, Dunbar P, Johnson J, Halliday-Mahar S, Pattar R, Ur, E. Development of clinical indicators for type 2 diabetes. Canadian Pharm Journal 141(2):120-128 (2008)
76 Brown R, Thompson HJ, Imran SA, Ur E, Wilkinson M. Traumatic brain injury induces adipokine gene expression in rat brain. Neurosci Lett. 432(1):73-8 (2008)
75 Brown R, Imran SA, Ur E, Wilkinson M. Valproic acid and CEBPa-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology 88(1):25-34 (2008)
74 Brown RE, Imran SA, Ur E, Wilkinson M. KiSS-1 mRNA in adipose tissue is regulated by sex hormones and food intake. Mol Cell Endocrinol 281:64-72 (2008)
73 Wilkinson M, Brown R, Imran SA, Ur E. Adipokine gene expression in brain and pituitary gland. Neuroendocrinology 86(3):191-209 (2007)
72 Imran SA, Ur E, Clark DB. Managing prolactin-secreting adenomas during pregnancy. Can Fam Physician 53(4):653-8 (2007)
71 Brown R, Imran SA, Belsham DD, Ur E, Wilkinson M. Adipokine gene expression in a novel hypothalamic neuronal cell line: resistin-dependent regulation of fasting-induced adipose factor and SOCS-3. Neuroendocrinology 85(4):232-41 (2007)
70 Lau DC, Douketis JD, Morrison KM, Hramiak IM, Shama AM, Ur E: Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 176(8):S1-13. (2007)
69 Hegele RA, Ur E, Ransom TP, Cao H. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clin Genet. 70(4):360-2. (2006)
68 Kahn SE and Adopt Study Group (Ur E). Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 355(23):2427-43 (2006)
67 Viberti G and ADOPT Study Group (Ur E). A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med 23(12):1289-94( 2006)
66 Kahn SE and ADOPT Study Group (Ur E). Obesity is a major determinant of the association of C- reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes, Vol. 55 (2006)
65 Wiesner G, Brown RE, Robertson GS, Imran SA, Ur E, Wilkinson M. Increased expression of the adipokine genes resistin and fasting0induced adipose factor in hypoxic/ischaemic mouse brain. Neuroreport. 31;17(11):1195-8 (2006)
64 Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes-an effect independent of homocysteine-lowering. Vasc Med.11(2):101-9 (2006)
63 Behn A, Ur E. The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol. 21(4):353-60 (2006)
62 Ur E, Serri O, Legg K, Murphy LJ, Ezzat S. Canadian guidelines for the management of adult growth hormone deficiency. Clin Invest Med. 29(2):83-90 (2006)
61 Ezzat S, Serri O, Chik CL, Johnson MD, Beauregard H, Marcovitz S, Nyomba BL, Ramirex JR, Ur E. Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin Invest Med. 29(1):29-39.(2006)
60 Shu DH, Ransom TP, O'Connell CM, Cox JL, Kaiser SM, Gee SA, Rowe RC, Ur E, Imran SA. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Cardiovasc Diabetol 7;5:8 (2006)
59 Brown R, Morash B, Ur E, Wilkinson M. RNAi-mediated silencing of leptin gene expression increases cell death in C6 glioblastoma cells. Brain Res Mol Brain Res. 139(2):357-60 (2005)
58 Wilkinson M, Wilkinson D, Wiesner G, Morash B, Ur E. Hypothalamic resistin immunoreactivty is reduced by obesity in the mouse: co-localization with alpha-melanostimulating hormone. Neuroendocrinology. 81(1):19-30 (2005)
57 Brown R, Wiesner G, Ur E, Wilkinson M. Pituitary resistin gene expression is upregulated in vitro and in vivo by dexamethasone but is unaffected by rosiglitazone. Neuroendocrinology 81(1):41- 8 (2005)
56 Harris SB, Dawson KG, Leiter LA, Houlden RL, Ur E, Capes SE, Mahon J. Erickson J, Lank CN, Lillie D. An Evidence-Based Approach to Screening and Management of Diabetes: A Case-Based Example of the Implementation of Clinical Practice Guidelines. Diabetes Risk Today (2005).
55 McIntyre RS, Leiter L, Yale JF, Lau D, Stip E, Ur E, Poulin MJ, Corenblum B, Cook P, Konarski JZ. Schizophrenia, Glycemia and Antipsychotic Medications: An Expert Consensus Review. Canadian Journal of Diabetes. 29(2):113-121 (2005)
54 Drouin P, Standl E. for the Diamicron MR Study Group (Ur E) Gliclazide modified release:results of a 2-year study in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 6:414-421 (2004)
53 Imran SA, Malmberg K, Cox JL, Ransom TP, Ur E. An overview of the role iof insulin in the treatment of hyperglycemia during acute mycardial ischemia. Can J Cardiol 20:1361-5 (2004)
52 Morash BA, Ur E, Wiesner G, Roy J, Wilkinson M. Pituitary resistin gene expression: effects of age, gender and obesity. Neurroendocrinology 79:149-56 (2004)
51 Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 180:R1-6 (2004)
50 Ur E. Prevention and Screening. Diabetes Risk Today (2004).
49 Riddle MC et al (Ur E). The Treat-to-Target Trial. Diabetes Care. 26(11):3080-3086 (2003)
48 Morash BA, Imran A, Wilkinson D, Ur E, Wilkinson M. Leptin receptors are developmentally regulated in rat pituitary and hypothalamus. Mol Cell Endocrinol) 210:1-8 (2003)
47 Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and Management of Hyperprolactinemia. CMAJ 169: 575-81 (2003)
46 Imran SA, Cox JL, Ur E. Diabetes control among patients presenting with acute myocardial infarction in a Canadian tertiary health care setting. Can J Cardiol 19:1407-10 (2003)
45 Imran SA, Ur E. Panhypopituitarism presenting with pleuropericardial effusions and hypoalbuminemia. The Endocrinologist 13:91-94 (2003)
44 Stuckey BG et al (Ur E). Sildenafil Citrate for Treatment of Erectile Dysfunction in Men with type 1 Diabetes. Diabetes Care 26(2):279-284 (2003)
43 McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26:124-31 (2003)
42 Morash B, Wilkinson M, Ur E. Resistin Expression and Regulation in Mouse Pituitary. FEBS Letters 526:26-30 (2002)
41 Ur E, Wilkinson D, Morash B, Wilkinson M. Leptin imunoreactivity is localized to neurons in rat brain. Neuroendocrinology 75:264-72 (2002)
40 Lawlor D, Vandewater D, Ur E Diabetes Case Management. Canadian Nurse 98:27-30 (2002)
39 Ransom T, Ur E. Measuring the effect of sibutramine for weight loss. JAMA 287:449-450 (2002)
38 Miles JM. et al (Ur E). Effect of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Treated with Metformin. Diabetes Care 25(7):1123-1128 (2002)
37 Morash B, Ur E, Wilkinson M Pituitary Leptin Gene Expression is Reduced by Neonatal Androgenization of female Rats. Pituitary 4:63-70 (2001).
36 Ur E, Wilkinson M. (Endocrine/Neuroendocrine Signals of Energy Stores. International Journal of Obesity S5:30-4 (2001)
35 Morash B, Murphy P, Ur E, Wilkinson M. Ontogeny of leptin gene expression in rat brain and pituitary. Molecular and Cellular Endocrinology 185:151-159 (2001)
34 Imran SA, Ur E. Clinical Update: Therapeutic Approaches to Type 2 diabetes. Canadian Diabetes 2001 14:3-7 (2001)
33 Ur E, Shlossberg A. Do Statins Reduce the Risk for Diabetes by Improving Exercise Capacity. Circulation 104:104-5 (2001)
32 Imran SA, Ur E. Therapeutic Approaches to Type 2 Diabetes. Drugs and Therapeutics for Maritime Practitioners. 24:2 (2001)
31 Li AW, Morash B, Hollenberg AN, Ur E, Wilkinson M, Murphy PR. Transcriptional regulation of the leptin gene promoter in rat GH3 pituitary and C6 glioma cells. Molecular and Cellular Endocrinology. 176:57-65 (2001)
30 Patel YC, Ezzat S, Chik C, Rorstad O, Serri O, Ur E, Wilkins GE. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clinical and Investigative Medicine 23:172-87 (2000).
29 Ur E. Drug Treatment of Obesity Canadian Journal of Diabetes Care 24:79-85 (2000)
28 Morash B, Johnston J, Li A, Murphy P, Ur E, Wilkinson M. Regulation of leptin gene expression in the C6 gliobastoma cell line. Molecular and Cellular Endocrinology 165: 97-105 (2000)
27 Crouse JR, et al (Ur E). Effects of High Doses of Simvastatin and Atorvastatin on High-Density Lipoprotein Cholesterol and Apolipoprotein A-1. Am J Cardiol 15;83:1476-1477 (1999)
26 Morash B, Li A, Murphy P, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary. Endocrinology 140: 5995-5998 (1999)
25 Ur E .Macrovascular Disease in Diabetes: Pathophysiology and Management. Canadian Diabetes 11 (2). (1998)
24 Costa A, Poma A, Martignoni E, Nappi G, Ur E, Grossman A. Stimulation of Corticotrophin- releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants. Neuroreport 8: 1131-1134. (1997)
23 Ur E, Wright DM, Bouloux PMG, Grossman A. Effect of Spiradoline (U-62066E), a kappa-opioid agonist, on psychological and neuroendocrine function in man. British Journal of Pharmacology 120:781-784 (1997)
22 Ur E, Grossman A, Depres JP Hypothesis: obesity results as a consequence of glucocorticoid induced leptin resistance. Hormone and Metabolic Research 28:744-747 (1996)
21 Ezzat S, Wilkins GE, Patel Y, Ur E, Rorstad OP, Serri OThe diagnosis and management of Acromegaly: A Canadian Consensus Report. Journal of Clinical Investigation 19 (4):259-70. (1996)
20 Cadigan DG, Hollett PD, Collingwood PW, Ur E. Imaging of a mediastinal thymic carcinoid tumor with radiolabelled somatostatin analogue. Clinical Nuclear Medicine 21 (6):487-488 (1996)
19 Hollett PD, Ur E. Applications of Radioactive Scanning in Neuroendocrinology. Current Opinion in Endocrinology & Diabetes: Multihormonal Systems Disorders. Vol 2 (1995)
18 Ur E, Capstick C, McLoughlin L, Rees LH, Checkley S, Grossman A, Besser GM Continuous infusion of CRH in the absence of glucorticoid feedback. Neuroendocrinology 61:191-197 (1995)
17 Adshead GA, Ur E. X And The Single Girl: Legal and Ethical Questions in Testicular Feminisation Syndrome. Journal of Medical Ethics (1994)
16 Woods R, Grossman A, Saphier P, Kennedy K, Ur E, Behan D, Potter E, Vale W, Lowry P J. Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. Journal of Clinical Endocrinology and Metabolism 78:73-76 (1994)
15 King CMP, Bomanji J, Ur E, Wass JAH, Grossman A, Besser GM, Reznek RH Imaging Neuroendocrine Tumours with Radiolabelled Somatostatin Analogues and X-ray Computed Tomography: a Comparative Study. Clinical Radiology 48:386-391 (1993)
14 Bomanji J, Britton KE, Ur E, Hawkins L, Grossman AB, Besser GM. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I- metaiodobenzylguanidine. Nuclear Medicine Communications 14:856-861 (1993)
13 Blake KD, Kirk J, Ur E. Growth in CHARGE Association. Archives of Diseases of Childhood 68(4):508 9 (1993)
12 Ur E, Bomanji J, Mather SJ, Britton KE, Wass JAH, Grossman AB, Besser GM Localisation of neuroendocrine tumours of the carcinoid type and insulinomas using radiolabelled somatostatin analogues:123I-TOCT and 111In-DOCT. Clinical Endocrinology 38:501-506 (1993)
11 Walker JD, Grossman A, Anderson JV, Ur E, Trainer PJ, Doniach I, Wass JAH, Besser GM Malignant Prolactinoma with Extracranial Metastases. Clinical Endocrinology 38:411-419 (1993)
10 Bomanji J, Ur E, Mather S, Moyes J, Ellison D, Grossman A, Britton KE, Besser GM. A Scintigraphic comparison of 123-I-meta-iodobenzylguanidine (MIBG) and an 123-I labeled somatostatin analogue (Tyr-3-octreotide) in metastatic carcinoid tumours. Journal of Nuclear Medicine 33:1121-1124 (1992)
9 Ur E, Grossman A. Corticotrophin Releasing Hormone in Health and Disease. Acta Endocrinologica 127:193-199 A (1992)
8 Ur E, White PD, Grossman A. The Role of Cytokines in Depression and Chronic Fatigue Syndrome: An Hypothesis. European Archives of Neurosciences and Psychiatry 241:317-322 (1992)
7 Ur E, Dinan T, O'Keane V, Clare AW, McLoughlin L, Rees LH, Turner TH, Grossman A, Besser GM. The effect of metyrapone on the pituitary-adrenal axis in depression: relation to dexamethasone suppressor status. Neuroendocrinology 56:533-538 (1992)
6 Ur E, Turner TH, Goodwin TJ, Grossman A, Besser GM. Mania in Association with Hydrocortisone Replacement for Addisons Disease. Postgraduate Medical Journal 68: 41-43. (1992)
5 Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Wass JH, Grossman A, Besser GM Pituitary Imaging Using an 123-I Labelled Analogue of Somatostatin in Acromegaly. Clinical Endocrinology 36: 147-150. (1992)
4 Ur E. The Hypothalamo-Somatotrophic Axis in Depression. Current Medical Literature: Growth and Growth Factors Vol 6,No 6:167-170 (1992)
3 Bomanji J, Moyes J, Ur E, Mather S, Britton KE, Besser GM. Scintigraphy of carcinoid tumors with 123I somatostatin analog (tyr 3 octreotide) and 123I mibg. Nucl Med Commun 12:286 (1991)
2 Ur E, Faria MS, Anderson JV, Besser GM, Grossman A. Atrial Natriuretic Peptide in Physiological Doses Does Not Inhibit the ACTH or Cortisol Response to Corticotropin Releasing Hormone 41 in Normal Human Subjects. Journal of Endocrinology 131: 163-167 (1991)
1 Turner TH, Ur E, Grossman A. Naloxone has no effect on humoral responses to ECT in man. Psychiatry Research 22:207-212 (1987)